Brief: Contrafect Announces FDA's Breakthrough Therapy Designation To Exebacase
24/02/2020 12:24
Feb 24 (Reuters) - ContraFect Corp CFRX.O :
* CONTRAFECT ANNOUNCES U.S. FDA GRANTS BREAKTHROUGH THERAPY
DESIGNATION TO EXEBACASE FOR THE TREATMENT OF
METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) BACTEREMIA,
INCLUDING RIGHT-SIDED ENDOCARDITIS
Source text for Eikon: ID:nGNX9mWVlz
Further company coverage: CFRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CONTRAFECT
See all newsBrief: Contrafect Corp - On Nov 7, Co Received Delisting Notification From Nasdaq Hearings Advisor Stating That Panel Determined To Delist Co's Common Stock
Brief: ContraFect Says Selling Securityholder May Offer And Selling Up To 7 Mln Shares In Aggregate Of Common Stock
Brief: Contrafect Announces FDA Clearance Of CF-370 IND Application To Proceed With Phase 1 Clinical Study
Brief: Contrafect Corp Says On Sept 21, Notified By Nasdaq, That Co Not In Compliance With The Minimum Bid Price Requirement
Brief: Contrafect Announces Submission Of Ind Application To The FDA For Its Development Candidate Cf-370